Xponance Inc. Purchases 15,418 Shares of Bath & Body Works, Inc. (NYSE:BBWI)

Xponance Inc. boosted its holdings in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 155.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,326 shares of the company's stock after purchasing an additional 15,418 shares during the period. Xponance Inc.'s holdings in Bath & Body Works were worth $768,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Michigan Retirement System bought a new position in Bath & Body Works during the 1st quarter worth approximately $1,571,000. Cerity Partners LLC raised its position in shares of Bath & Body Works by 126.4% during the 1st quarter. Cerity Partners LLC now owns 79,559 shares of the company's stock worth $2,412,000 after purchasing an additional 44,414 shares during the period. Allworth Financial LP raised its position in shares of Bath & Body Works by 3,679.4% during the 1st quarter. Allworth Financial LP now owns 8,617 shares of the company's stock worth $256,000 after purchasing an additional 8,389 shares during the period. New Mexico Educational Retirement Board acquired a new stake in shares of Bath & Body Works during the 1st quarter worth approximately $1,295,000. Finally, TD Private Client Wealth LLC raised its position in shares of Bath & Body Works by 44.3% during the 1st quarter. TD Private Client Wealth LLC now owns 3,305 shares of the company's stock worth $100,000 after purchasing an additional 1,015 shares during the period. Hedge funds and other institutional investors own 95.14% of the company's stock.

Bath & Body Works Price Performance

Shares of NYSE BBWI traded up $0.08 during trading hours on Friday, hitting $31.79. 4,055,565 shares of the company's stock were exchanged, compared to its average volume of 5,262,039. Bath & Body Works, Inc. has a 1-year low of $24.94 and a 1-year high of $41.87. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of 8.48, a PEG ratio of 1.07 and a beta of 1.72. The company's 50-day moving average price is $30.16 and its 200-day moving average price is $32.25.

Bath & Body Works (NYSE:BBWI - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.02. Bath & Body Works had a negative return on equity of 47.44% and a net margin of 11.10%. The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period in the prior year, the company posted $0.38 EPS. The company's revenue was up 2.9% compared to the same quarter last year. On average, research analysts expect that Bath & Body Works, Inc. will post 3.3 earnings per share for the current year.

Bath & Body Works Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 20th. Shareholders of record on Friday, June 6th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend was Friday, June 6th. Bath & Body Works's dividend payout ratio is 21.33%.

Analyst Upgrades and Downgrades

BBWI has been the topic of several research analyst reports. Raymond James Financial lowered their price target on Bath & Body Works from $46.00 to $37.00 and set an "outperform" rating on the stock in a research report on Thursday, April 17th. JPMorgan Chase & Co. lifted their price target on Bath & Body Works from $41.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, May 19th. Telsey Advisory Group reiterated an "outperform" rating and set a $38.00 price target (down from $43.00) on shares of Bath & Body Works in a research report on Thursday, May 29th. Barclays lowered their price target on Bath & Body Works from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research report on Friday, May 30th. Finally, UBS Group lifted their price target on Bath & Body Works from $32.00 to $36.00 and gave the company a "neutral" rating in a research report on Tuesday, May 20th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Bath & Body Works currently has an average rating of "Moderate Buy" and an average target price of $42.00.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.